|Summary sheet: Fasoracetam|
|Common names||Fasoracetam, NS-105, LAM-105, NFC-1,|
|Chemical class||Racetam / Piperidine|
|Routes of Administration|
Fasoracetam (NS-105, NFC-1) is a nootropic agent belonging to the racetam family of drugs. Although it is one of the first known and synthesized derivatives of piracetam, its research and efficacy in humans is limited.
Fasoracetam upregulates GABA receptors and may also be beneficial for ADHD either alone or in combination with stimulant medication.
Anecdotal reports of fasoracetam supplementation for nootropic purposes range from 20-100mg/day while clinical trials have used doses up to 800mg/day (400mg BID) for the treatment of ADHD in adolescents with glutamate hypofunction due to mGluR mutations.
Fasoracetam has demonstrated antiamnesic properties in animal models.
Fasoracetam is a pyrrolidinone compound of the racetam family.
Fasoracetam modulates cyclic adenosine monophosphate (cAMP) activity via activation of metabotropic glutamate receptors (mGlu). It appears to have activity at all three subclasses of mGlu receptors, with group I activation exhibiting a facilitatory effect, and groups II and III an inhibitory effect on cAMP.
In comparison to the effects of other racetam nootropics such as noopept, this compound can be described as focusing primarily on physical stimulation over that of cognitive stimulation. Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), a literature which relies on collected anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely with higher doses and may include serious injury or death.
- The effects of fasoracetam are anecdotally reported to foster creativity and holistic thinking as well as reducing anxiety and depression.
Toxicity and harm potential
In one clinical trial, fasoracetam appeared to be well-tolerated at doses up to 800mg/day, however, the subjects were identified as possibly having glutamate hypofunction as a result of mutations in genes encoding variants of the metabotropic glutamate receptor.
One case report exists of an overdose consisting of a large dose of phenibut (10g) in combination with an unknown quantity of fasoracetam. Patient was found unconscious on the sidewalk and bradycardia (slowed heartbeat) was noted at the hospital, requiring the use of subcutaneous pacing pads. The patient recovered from the physical symptoms and was referred to a psychiatric unit for evaluation and treatment of an underlying condition. The case report notes that bradycardia is not typically reported in phenibut overdose and could possibly be related to fasoracetam.
Tolerance and addiction potential
This substance has little history of human use. While tolerance and addiction or physical dependence have not been reported, the data on long-term use is lacking.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders | https://www.ncbi.nlm.nih.gov/pubmed/20166767
- Difference in learning and retention by Albino Swiss mice. Part III. Effect of some brain stimulants | https://www.ncbi.nlm.nih.gov/pubmed/3736279
- Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling | https://www.nature.com/articles/s41467-017-02244-2
- Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons. | https://www.ncbi.nlm.nih.gov/pubmed/11259610